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ARTICLE
MHC matching improves engraftment of
iPSC-derived neurons in non-human primates
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The banking of human leukocyte antigen (HLA)-homozygous-induced pluripotent stem cells
(iPSCs) is considered a future clinical strategy for HLA-matched cell transplantation to
reduce immunological graft rejection. Here we show the efﬁcacy of major histocompatibility
complex (MHC)-matched allogeneic neural cell grafting in the brain, which is considered a
less immune-responsive tissue, using iPSCs derived from an MHC homozygous cynomolgus
macaque. Positron emission tomography imaging reveals neuroinﬂammation associated with
an immune response against MHC-mismatched grafted cells. Immunohistological analyses
reveal that MHC-matching reduces the immune response by suppressing the accumulation
of microglia (Iba-1+) and lymphocytes (CD45+) into the grafts. Consequently, MHC-
matching increases the survival of grafted dopamine neurons (tyrosine hydroxylase: TH+).
The effect of an immunosuppressant, Tacrolimus, is also conﬁrmed in the same experimental
setting. Our results demonstrate the rationale for MHC-matching in neural cell grafting to the
brain and its feasibility in a clinical setting.
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Cell therapy using pluripotent stem cells (PSCs) isconsidered a promising therapeutic application for manydiseases1 including Parkinson’s disease (PD). After more
than two decades of fetal neural cell grafting2–4, cell therapy for
PD with PSCs is expected to soon realize clinical application5. It
has been shown that autologous transplantation is ideal from an
immunological point of view6–8. Practically speaking, however,
autologous transplantation at clinical grade that meets good
manufacturing practice, quality assurance, and regulatory com-
pliance is unlikely to become standard therapy due to its high cost
and long preparation time per patient9. Another concern
regarding autologous transplantation is the disease sensitivity of
the donor cells from patients who have disease-speciﬁc genetic
backgrounds. Allogeneic transplantation is therefore a preferred
option. Major histocompatibility complex (MHC), or human
leukocyte antigen (HLA) in humans, is expressed on the cell
surface and is recognized by T-lymphocytes such that it plays a
crucial role in the immune response after allogeneic transplan-
tation. HLA haplotypes are determined by combinations of
>16,000 HLA paternal and maternal alleles10. In organ trans-
plantation such as kidney and bone marrow, matching HLA-A,
-B, and -DR, improves the graft survival rates11–13. A recent
report showed that MHC-matched allogeneic induced pluripotent
stem cells (iPSC)-derived cardiomyocytes survived and func-
tioned in monkeys that received immunosuppressive treatment14.
These facts are consistent with the notion that HLA-matched
transplantation using HLA-homozygous iPSCs could reduce
immunological rejection9, 15, 16. For clinical application, such
HLA-homozygous iPSCs would need to be banked. It is estimated
that a tissue bank from 10 selected homozygote HLA-typed
volunteers would match 37.7% of the population in the UK, and
150 similar volunteers would match 93%15. In other estimates,
50 lines would cover 90.7%17 or 73%16 of the Japanese popula-
tion. For more than 30 years, allogeneic fetal neural cell grafting
(HLA-mismatched transplantation) has been performed in
clinical and basic studies for PD, and the neural grafts have
shown good survival over a long time3–5. Yet some reports have
suggested that immune responses to the neural grafts can affect
graft survival and function2, 3. We therefore aimed to examine the
effects of MHC matching in neural cell transplantation.
Here we show MHC matching reduces the immune response
with microglia and lymphocytes, and increases the survival of
iPSC-derived dopamine (DA) neurons in non-human primates
(NHPs).
Results
Preparation of MHC-matched donor cells. Our experimental
design is described in Fig. 1a. Two iPSC lines, 1123C1-G and
1335A1, derived from cynomolgus macaques with homozygous
MHC haplotypes (Mafa-HT1 and Mafa-HT4, respectively; Mafa
is a cynomolgus macaque’s MHC) were differentiated into DA
neurons. The DA neurons were transplanted to monkeys in
which at least one of the alleles was identical to the homozygotes
for MHC-matched transplantation (16 animals in total. Figs. 1a
and 2a; Supplementary Table 1, see also Methods section). This
setting is referred to as the experimental model of HLA-matched
allogeneic transplantation for PD. In the HT1 series of experi-
ments (Cont#1–4 and Hetero#1–4), we used a donor cell line,
1123C1-G, to examine the effect of MHC matching. In the second
HT4 series of experiments, we used another cell line, 1335A1, to
conﬁrm the results of the HT1 series and also to examine the
effects of daily immunosuppression by Tacrolimus (Fig. 1).
Donor iPSCs were maintained on iMatrix and constantly
expressed pluripotent markers such as Oct4 and Nanog
(Fig. 2b–f) with normal karyotype (Supplementary Fig. 1a, b).
Both cell lines were differentiated into DA neural progenitors
expressing several markers of the midbrain ventral mesencephalic
phenotype, including Foxa2, Lmx1a, Nurr1, Corin, and MAP2, in
a time dependent manner (Fig. 2g–m, Supplementary Fig. 1c–l).
We transplanted the donor cells at differentiation day 28, and
their major component was DA progenitor cell (TuJ1+/Foxa2+).
The donor cells weakly expressed MHC class I, and interferon
gamma (IFN-γ) stimulation increased its expression (Fig. 2n, o).
On the other hand, the expression of MHC class II was below
physiological level even with IFN-γ stimulation.
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PET detected graft-induced neuroinﬂammation. We grafted
5 million cells divided in six tracts to the left putamen (Fig. 3a).
The grafts were detected as hypo- and hyper-intensity signals
in T1-weighted and T2-weighted magnetic resonance
imaging (MRI), respectively (Fig. 3b). We performed positron
emission tomography (PET) imaging using two kinds of probes,
11C-PK11195 (Figs. 3c and 4) and (S)-11C-ketoprohen
methyl ester ((S)-11C-KTP-Me; Fig. 5). These probes were
short-lived, radio-labeled, and sensitive to speciﬁc biomarkers.
Therefore, PET scanning allowed us to repeatedly and
non-invasively monitor the concentration and location of the
biomarker of interest. The two probes were expected to detect
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Fig. 2 MHC genotypes of donors and recipients, and differentiation of MHC-homo iPSC-derived donor cells. a MHC genotypes of the donor and hosts
in the ﬁrst (HT1 haplotype) and the second (HT4 haplotype) experiments. Representative pairs of hosts are shown. See also Supplementary Table 1.
b–f Characterization of MHC-homo iPSCs (1123C1-G). Phase contrast image (b), and ﬂuorescent images (DAPI, c) with immunostaining for GFP (d),
Nanog (e), and Oct4 (f). g–m Characterization of MHC-homo iPSC-derived dopamine neurons. An aggregate of donor cells at day 28 (g; phase contrast)
contained more than 99% of cells positive for a neural marker, PSA-NCAM (h; ﬂow cytometric analyses). i Quantitative PCR (qPCR) analysis of the
cells during differentiation. j–m Immunostaining of iPSC-DA neurons at day 39. Quantiﬁcation of immunocytochemical analysis for donor cells (m).
n, o Expression of MHCs on the donor cells analyzed by qPCR (n) and ﬂow cytometry (o). Scale bars: 100 μm (b–g, j–l), The data in i, m, n are shown
as means± SD (n= 4 independent experiments for i and 3 independent experiments for m, n)
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00926-5 ARTICLE
NATURE COMMUNICATIONS |8:  385 |DOI: 10.1038/s41467-017-00926-5 |www.nature.com/naturecommunications 3
neuroinﬂammation associated with an immune response by
targeting translocator protein (TSPO)18 and cyclooxygenase-1
(COX-1)19, respectively. The chronological quantiﬁcation of
11C-PK11195 binding potential (BP) in grafted putamen showed
a potential inﬂammatory immune response for 3 months
after transplantation (Figs. 3c, d and 4). Graft-host matching
signiﬁcantly affected the time course of BP in the grafted putamen
(F(1, 10)= 5.159, P= 0.046, one-way repeated measure analysis
of variance (ANOVA)), and MHC-mismatched grafts had BP
that were ~50% higher (0.317± 0.022; mean± SEM) than those
of matched grafts (0.201± 0.024) at 3 months after transplanta-
tion (corrected P= 0.005) (Fig. 3d). We also conﬁrmed the
effect of graft-host matching was suppressed by Tacrolimus.
There was a signiﬁcant interaction between graft-host matching
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Fig. 4 Binding potential (BP) images of 11C-PK11195 in positron emission tomography (PET). a Representative slices of BP images sectioned coronally
and axially are shown for all animals and time points before (Pre) or after transplantation (1W, 1M, 2M, and 3M). b Chronological change of BP in the
left (grafted side) and right (control side) putamen of each monkey. BP values ranging from 0 to 1 are presented with the color bar. c Spearman correlation
analyses of 11C-PK11195 PET at 3 months and immunohistological results at 4 months. BP in each grafted putamen plotted vs. the average
immunohistochemical results of Iba-1, CD45, MHC Class II, and IgG deposits from individual animals. Results from Spearman correlation analysis are given
as r- and P-values in each graph. Tendencies of correlations are shown by linear regression lines for CD45 and IgG deposits. M months after
transplantation, O.D.: optical density of the whole putamen, PK: 11C-PK11195, pre: preoperative analysis, W: weeks after transplantation
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and Tacrolimus (F(1, 12)= 6.98, P= 0.022, two-way repeated
measure ANOVA), and when monkeys were treated with
Tacrolimus, the BP of the mismatched graft at 3 months was
decreased by ~50% (0.176± 0.036) (corrected P= 0.006)
such that it did not differ from the BP of matched grafts
(Fig. 3d). A similar but insigniﬁcant pattern was observed in
(S)-11C-KTP-Me PET imaging, suggesting that the COX-1 is
also involved in the inﬂammatory immune response to
MHC-mismatched grafts (Fig. 5).
Histological analyses at 4 months after transplantation. For
survival of the grafted cells in allogeneic transplantation, acute
and sub-acute immune responses are critical and usually occur at
2–3 months after transplantation10. Therefore, we performed
histological examination at 4 months after transplantation.
An immunological response was indicated by the accumulation
of host-derived activated microglia expressing Iba-1 and MHC
class II and the inﬁltration of CD45+ leukocytes in the grafts
(Figs. 6 and 7). More than 99% of the donor cells were committed
to neural lineage before transplantation (Fig. 2h), and no GFP+
grafted cells expressed Iba-1 or CD45 in vivo (Fig. 6h, i), indi-
cating that immune-responsive cells were derived from the host
brain. Besides a cellular immune response, a humoral immune
response was deduced from IgG deposits around the grafts.
Statistical analysis showed signiﬁcantly less Iba-1+ cell accumu-
lation (P< 0.0001, n= 24 tracts in the HT1 series, paired t-test;
P= 0.0005, n= 12 tracts in the HT4 series, one-way ANOVA
with Tukey’s multiple comparisons test; P= 0.004, n= 6 animals
in the HT1 and HT4 series, paired t-test, respectively) and less
CD45+ leukocyte inﬁltration (P= 0.029 in the HT1 series, paired
t-test; P< 0.0001 in the HT4 series one-way ANOVA with
Tukey’s multiple comparisons test; P= 0.023, n= 6 animals in
the HT1 and HT4 series, paired t-test, respectively) in the
MHC-matched grafts than MHC-mismatched ones (Fig. 7a–f).
The BP of 11C-PK11195 in the PET study correlated with
histological ﬁndings (Fig. 4c). The majority of inﬁltrating CD45+
cells was CD3+ T cells, of which 60–80% were CD4+ helper
T cells and the rest CD8+ cytotoxic T cells (Fig. 6g). Immuno-
suppression with Tacrolimus in MHC-mismatched transplanta-
tion avoided the inﬁltration of CD45+ lymphocytes (Figs. 6b
and 7d, h). Mesencephalic DA neurons were detected in the grafts
that were positive for TH, Foxa2, and Girk2 (Fig. 8a–e). Statistical
analysis showed more TH+ cells survived in the MHC-matched
grafts compared with MHC-mismatched ones in both the HT1
and the HT4 series (Fig. 8f, g, P= 0.004, n= 24 tracts, paired
t-test; P= 0.0001, n= 12 tracts, one-way ANOVA with Tukey’s
multiple comparisons test, respectively). The density of mature
DA neurons (TH+ cells/mm3) that survived was signiﬁcantly
higher in MHC-match grafts than MHC-mismatch ones (Fig. 8l,
P= 0.008, n= 6 animals, paired t-test). In contrast, there was no
signiﬁcant difference in the density of surviving Foxa2+ cells
(Fig. 8m, P= 0.41, n= 6 animals, paired t-test), suggesting that-
mature DA neurons (TH+, Foxa2+) are more sensitive to
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immune responses than other types of grafted cells (TH−,
Foxa2+). These results are consistent with previous reports that
found DA neurons in substantia nigra pars compacta (SNc) are
speciﬁcally sensitive to a variety of stresses such as mitochondrial
oxidant stress20 and mechanical stress21. We performed a
classical one-way mixed lymphocyte reaction using peripheral
blood mononuclear cells (PBMCs) to predict the immune
response, but found no signiﬁcant correlation with the histolo-
gical ﬁndings (Supplementary Fig. 2).
Discussion
Although the brain is considered a less immune-responsive
tissue22, the present study clearly shows MHC matching can
200,000 30,000 300,000
200,000
100,000
0
30,000
20,000
10,000
0
20,000
10,000
0
Iba-1a
e
g
j
l m
k
h i
f
b c d
Iba-1 density
Iba-1
IgG PK11195 (3M)
CD45 MHC-ll
CD45 density
Iba-1 CD45 CD45
150,000
** *
***
****
*
* ****
****
****
100,000
Ce
lls
/m
m
3
Ce
lls
/m
m
3
Ce
lls
/tr
a
ct
Ce
lls
/tr
a
ct
Ce
lls
/tr
a
ct
Ce
lls
/tr
a
ct
50,000
0
200,000
60,000
40,000
20,000
0
0 255
Optical density of putamen: P’
0.6 0.5
0.4
0.3
0.2
Bi
nd
in
g 
po
te
nt
ia
l
0.1
0.0
100
Morphology of Iba-1+ cells%
80
60
40
20
0
1 2 3 4 5
Cont # Cont #
+Tacrolimus
Hetero # Hetero #
6 1 2 3 4 5 6 7 8 7 8
Round
Ameboid
Rest
0.4
O
pt
ica
l d
en
sit
y
0.2
0.0
40,000
#1
#2
#3
#4
#5
#6
1123C1-G (HT1)
#6
#7
#8
#5#1
#2
#3
#4
1123C1-G (HT1)
1335A1 (HT4)
1335A1 (HT4)
30,000
20,000
10,000
0
150,000
150,000
100,000
50,000
0
0.3
0.2
O
pt
ica
l d
en
sit
y
0.1
0.0
–0.1
100,000
Ce
lls
/m
m
3
Ce
lls
/m
m
3
50,000
0
Mismatch Match
Mismatch Match
Mismatch Match Mismatch
+Tac
Match
+Tac
Mismatch Match Mismatch
+Tac
Match
+Tac
Mismatch Match Mismatch
+Tac
Match
+Tac
Mismatch Match Mismatch
+Tac
Match
+Tac
Mismatch Match Mismatch
+Tac
Match
+Tac
Mismatch Match
Mismatch Match Mismatch Match Mismatch MatchMismatch
+Tac
Mismatch
+Tac
Match
+Tac
Match
+Tac
P’ =
c - p
b
p
b
c
Fig. 7 Quantitative analysis showed the effect of MHC matching on decreasing immune response after transplantation. a–d Quantitative analyses of Iba-1+
microglia (a, b) and CD45+ leukocytes (c, d) in the grafts; HT1 (a, c) and HT4 (b, d) experiments. e, f Averaged value plots of Iba-1+ (e) and CD45+ (f) cell
densities in the grafts of individual monkeys. Combined data of Mismatch and Match from the HT1 and the HT4 series. g–j Averaged value plots in
individual monkeys for the expressions of Iba-1 (g), CD45 (h), MHC class II (i), IgG deposits (j), 11C-PK11195 (k). Mismatch (n= 6), Match (n= 6),
Mismatch + Tacrolimus (n= 2), and Match + Tacrolimus (n= 2) experiments were analyzed. HT1 (#1–#4) and HT4 series (#5–#8) are separately shown
in each graph. l The calculation method of optical density for MHC class II and IgG deposit staining. m Morphological analysis of Iba-1+ microglia.
Resting microglia change their shape from ameboid to round upon activation. Data are presented as means± SEM (n= 24 tracts for a, c; n= 12 tracts
for b, d; n= 6 animals for e, f). Paired t-tests were performed for the HT1 experiment: ****P< 0.0001 (a), *P= 0.029 (c), **P= 0.004 (e), *P= 0.023 (f).
One-way ANOVA with Tukey’s multiple comparisons test was performed for the HT4 experiment: ***P= 0.0005 (b), *P= 0.0496 (b), ***P< 0.0001 (d).
Tac: Tacrolimus, See also Fig. 6
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00926-5
8 NATURE COMMUNICATIONS | 8:  385 |DOI: 10.1038/s41467-017-00926-5 |www.nature.com/naturecommunications
reduce the number of Iba-1+ microglia and CD45+ lymphocytes
and increase the number of surviving TH+ neurons in the
grafts (Figs. 7a–d and 8f, g). One animal (MHC-match
Hetero#3) showed a slight immune response (Fig. 7g–j). Possible
mechanisms for immune responses in this MHC-matched animal
include an indirect pathway caused by minor antigens instead
of MHC23 or innate immunity caused by natural killer (NK)
cells24 and a complementary system. Although previous mouse
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experiments reported that NK cells attack MHC-matched grafts
more strongly than MHC-mismatched ones through a mechan-
ism called hybrid resistance25, 26, it is controversial whether
the same mechanism exists in humans27. Furthermore, we
found no difference in NK cell inﬁltration between the grafts of
MHC-match Hetero#3 and MHC-mismatched Cont#2 and #4
(Fig. 6j–p). Additionally, Tacrolimus alone was effective at
preventing the inﬁltration of lymphocytes into the grafts. It has
been reported that MHC-mismatched grafts or human-derived
xenografts survived and functioned in neurotoxin-lesioned PD
monkeys with immunosuppression28, 29. In this study, we focused
on acute and sub-acute immune responses so that we could
perform histological analyses of immune-responsive cells. Even
if controlled with MHC matching or immune suppressant,
however, there is a chance that a late-onset immune response
may occur. Therefore, further studies are needed to address the
additional effects of MHC matching on synaptic formation and
consequent functional recovery.
Although MHC matching was statistically effective at reducing
the immune response, it did not completely evade the immune
response even in the brain. Based on this ﬁnding, we propose that
the combination of MHC matching and immunosuppression will
provide the best strategy to control the immune response.
Importantly, MHC matching may help to reduce the dose and
duration of immunosuppressive drugs. Our study also indicates
that PET studies would be helpful for detecting graft–host
interactions and adjusting immunosuppression in clinical cases.
Methods
Non-human primates. Sixteen purpose-bred male cynomolgus macaques
(Macaca fascicularis) were used as the recipients, and two cynomolgus macaques
were used as the donors. All animals were purchased from the Philippines
archipelago (INA Research Inc.). There exists an isolated Filipino macaque
population that has a limited variety of MHC polymorphisms compared with other
populations. Hence, MHC homozygous and MHC heterozygous monkeys are
frequently identiﬁed in this population30. The Mafa class I and II haplotypes of
all animals were previously characterized by the Sanger sequencing method and
high-resolution pyrosequencing14, 30. The donors were MHC homozygous. Four
heterozygous male animals with HT1 haplotype and another four heterozygous
animals with HT4 haplotype were used as recipients for the MHC-matched
transplantation (MHC-Match; hetero). The other eight recipient animals did not
have the same haplotype as the donors (MHC-mismatch; control) (Figs. 1a and 2a;
Supplementary Table 1). In Hetero#7 and Hetero#8 monkeys, the alleles of the
MHC class I, but not of MHC class II, were identical to the HT4 haplotype
(Supplementary Table 1). Because the expression of MHC class II in the donor cells
were below physiological level, those two monkeys were regarded as Hetero and
were assigned to the group with immunosuppression. Because the monkeys used in
this study were supplied from an isolated small colony and not from a closed
colony like experimental rodents, the diversity of minor antigens might be less than
of humans. On the other hand, it is known that the genetic polymorphism of
cynomolgus monkeys has more variability than that of humans because of the
longer evolutionary period (1.2 million years in cynomolgus monkey and 0.2–0.4
million years in human)31, 32. Furthermore, because this study focused on the
immune response and survival of grafted cells, we adopted unlesioned host
monkeys instead of neurotoxin-lesioned PD model, as it is difﬁcult to prepare a set
of equally lesioned PD monkeys due to the limited availability of MHC homo-
zygous animals. All procedures for animal care and experiments were approved by
the Institutional Animal Care and Use Committee of Animal Research Facility,
CiRA, Kyoto University (Permission Number: 10-8-9), and performed in
accordance with the Guidelines for Animal Experiments of Kyoto University, the
Institutional Animal Care and Use Committee of Kobe Institute in RIKEN, and the
Guide for the Care and Use of Laboratory Animals of the Institute of Laboratory
Animal Resources (ILAR; Washington, DC, USA).
Genotyping of MHC. Total RNA was isolated from peripheral blood cells using
TRIzol reagent (Invitrogen). complimentary DNA was synthesized using ReverTra
Ace (TOYOBO) after treatment of the isolated RNA with DNase I (Invitrogen).
A single MHC class I-speciﬁc primer pair in exons 2–4 (PCR product size: 514 or
517 bp) that could amplify all known MHC class I alleles and MHC class II locus-
speciﬁc primer sets that included polymorphic exon 2 in Mafa-DRB (420 bp),
Mafa-DQA1 (435 bp), Mafa-DQB1 (396 bp), Mafa-DPA1 (407 bp), and Mafa-
DPB1 (333, 336, or 339 bp) were used for massively parallel pyrosequencing14, 30.
After reverse transcriptase PCR ampliﬁcation using high-ﬁdelity KOD FX poly-
merase (TOYOBO), pyrosequencing of the PCR products was carried out using the
GS Junior system and amplicon sequencing protocol (Roche). MHC genotypes
were assigned by comparing the sequences to known MHC allele sequences at the
Immuno Polymorphism Database (http://www.ebi.ac.uk/ipd/index.html).
iPSCs. To generate iPSCs, PBMCs from the donor female macaque were trans-
fected with a combination of plasmid vectors (OCT4, SOX2, KLF4, L-MYC, LIN28,
shRNA for TP53, and EBNA1)6, 14. The established primate iPSC lines 1123C1 and
1335A1 were maintained on iMatrix (Nippi, Inc., Japan) with AK01 or AK02
medium (Ajinomoto, Japan)33. After 10 passages (P10), 1123C1 was transfected
with GFP to mark donor cells 1123C1-G. PB-EF1α-EGFP-IRES-PUROMYCIN
plasmid vector was transfected into the cells using the FuGENE HD system, and
puromycin was added to the medium to select the transfected cells (Fig. 2d). All
iPSCs were used before passage 40. We used 1123C1-G for the ﬁrst experiment and
1335A1 for the second experiment. For karyotype analysis, the iPSCs were treated
with 0.2 μg/ml colcemid for 2 h. The cells were collected by Accumax, incubated in
0.075 M KCl for 20 min, and ﬁxed with methanol and acetic acid (3:1). The
chromosome spreads were prepared and examined as standard protocol with
quinacrine mustard and Hoechst 33258 staining14.
Dopamine neuron induction. For Cont#1, #2, #5–#8 and Hetero#1, #2, #5–#8, the
primate iPSCs were differentiated into DA neurons using the modiﬁed SFEBq
method34 with dual SMAD inhibitors (Fig. 2h–k; Supplementary Fig. 1c–g)35, 36.
For Cont#3, #4, and Hetero#3, #4, the iPSCs were differentiated into DA neurons
using a modiﬁed protocol (Supplementary Fig. 1h–l) that was similar to the pro-
tocol for differentiating human iPSCs using an attachment culture on iMatrix37.
We transplanted the cells at day 28 of the differentiation. For in vitro analysis, we
dissociated the cells with Accumax (Innovative Cell Technologies) and replated
them on eight-well glass chamber slides coated with iMatrix or sliced the spheres
for immunostaining.
Transplantation. Floating aggregates (day 28) were harvested and dissociated into
small clumps of 20–30 cells with Accumax. The cells were suspended in the last
culture medium, which was Neurobasal medium with B27 and ascorbic acid (AA),
dbcAMP, glial cell line-derived neurotrophic factor (GDNF), and brain-derived
neurotrophic factor (BDNF). We also added a ROCK inhibitor, 10 μM Y27632,
to increase the survival of the donor cells. The suspension was prepared at the
concentration 2 × 105 cells/μl. Through a 22-gauge needle, we injected 4 μl of the
suspension using a Hamilton syringe. We made six (two coronal × three sagittal)
tracts of the injection in one side of the putamen. In total, 4.8 × 106 cells per animal
(8.0 × 105 cells/tract × 6 tracts) were injected into one side of the putamen
according to the coordinates decided by the MRI of each monkey. The same
volume of culture medium was injected to the contralateral side as the control.
After surgery, antibiotics were given for 3 days. Monkeys Cont#7–8, Hetero#7–8
received a daily intramuscular immunosuppressant (Tacrolimus, 0.05 mg/kg;
Astellas) from 1 day before the surgery until the day of killing to keep the blood
Fig. 8 Histological analysis detected more dopamine neural survival in MHC-matched transplantation. a, b Representative low magniﬁed views of staining
at 4 months after transplantation. Cont#4 and Hetero#4 from the HT1 experiments (a). Cont#5, Hetero#5, Cont#7, and Hetero#7 from the HT4
experiments (b). Representative view of grafts with Hematoxylin and Eosin (HE) staining (a, b) and DAB-Ni immunostaining for tyrosine hydroxylase
(TH; a, b) and Foxa2 (b). c–e TH (green), Foxa2 (c, magenta), and Girk2 (d, e, magenta) staining in the representative graft (Hetero#1). Magniﬁed view
(c, e) and lower magniﬁed view (d). f, g Quantitative analyses of TH+ cells (f, g), Foxa2 (h, i), and graft volume (j, k) in the grafts; HT1 (f, h, j; n= 24 tracts)
and HT4 (g, i, k; n= 12 tracts) experiments. l, m Averaged value plots of TH+ (g) and Foxa2+ (h) cell densities in the grafts of individual monkeys.
Combined data of Mismatch and Match from the HT1 and the HT4 series. n–p Averaged value plots in individual monkeys for the expressions of
tyrosine hydroxylase (TH, n), Foxa2 (o), and graft volume (p). Mismatch (n= 6), Match (n= 6), Mismatch + Tacrolimus (n= 2), and Match + Tacrolimus
(n= 2). Scale bar: 5 mm (a HE and TH, b HE), 1 mm (b, TH lower mag), 100 μm (b TH and Foxa2, d), and 50 μm (c, e). Quantitative data are presented
as means± SEM (n= 24 tracts for f, h, j; n= 12 for g, i, k; and n= 6 for l, m). Paired t-tests were performed for f, h, j, l, m: **P= 0.004 (f)
**P= 0.008 (l). One-way ANOVA with Tukey’s multiple comparisons test was performed for g, i, k: ****P< 0.0001 (g), ***P= 0.0001 (g), *P= 0.049 (g,
left), *P= 0.022 (g, right), *P= 0.025 (i, upper), **P= 0.006 (i), *P= 0.022 (i, lower), *P= 0.024 (k). Tac: Tacrolimus
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concentration of the drug at 10–20 ng/ml (Fig. 1b). Under deep anesthesia, the
animals were killed and perfused transcardially with 4% PFA after 4 months of
observation.
Immunohistochemistry. For in vivo studies, ﬁxed frozen brains were sliced at
40 μm thickness. The slices were immunologically stained using the free-ﬂoating
method. The primary antibodies used are listed in Supplementary Table 2. For
staining with CD3 and CD4 antibodies, we took an additional step for antigen
retrieval using 10 mM citrate buffer at 100 °C for 40 min. Fluorescent staining with
Alexa secondary antibodies (Invitrogen) were used. The cells were visualized using
a confocal laser microscope (LSM700, Zeiss). For 3, 3′-Diaminobenzidine-nickel
(DAB-Ni) staining, biotinylated secondary antibody and ABC Elite kit (Vector
Labs) was performed followed by 0.02% DAB, 0.6% nickel ammonium sulfate, and
0.0045% H2O2 incubation. For DAB-Ni and HE staining, we observed the samples
and took pictures with BZ-X700 (Keyence, Osaka, Japan). For DAB-Ni staining,
dead cells and debris are shown in brown, and positive signals are stained in dark
blue and black. The number of immunoreactive cells was quantiﬁed in every 18th
section throughout the grafts and surrounding tissue and corrected by using the
Abercrombie method.
Flow cytometric analysis. Cell aggregates were gently dissociated with Accumax
into a single-cell suspension and resuspended in phenol-free, Ca2+Mg2+-free
Hank’s balanced salt solution (HBSS; Invitrogen) containing 2% FBS and 20 mM
D-glucose (Wako). Samples were ﬁltered through cell-strainer caps (35 μm mesh;
BD Biosciences) and then subjected to surface marker staining using antibodies for
PSA-NCAM, HLA-ABC, and HLA-DR. The antibodies were added and incubated
at 4 °C for 20 min, and then cells were washed twice with HBSS buffer. Dead
cells and debris were excluded by 7-AAD staining. For staining with Foxa2-PE
antibodies, dissociated cells were ﬁxed with 4% PFA for 30 min, washed with
PBS(−) twice and re-suspended in BD Perm/Wash buffer (BD Biosciences)
according to the manufacturer’s protocol. The analysis was performed using a BD
LSRFortessa ﬂow cytometer, the FACSDiva software program (BD Biosciences),
and FlowJo (ver.8.8.6) ﬂow cytometry analysis software (Tree Star). HLA-ABC and
HLA-DR antibodies were used to detect monkey’s MHC class I and MHC class II
antigens, respectively.
Quantiﬁcation by optical density of the immune-stained sections. To quantify
the results of immunostaining for MHC class II and IgG deposits, optical density
was measured. IgG was deposited evenly in the immune-responded area and did
not take cellular form. There were some monkeys with strong MHC class II
response, which hampers accurate counting of the number of positive cells. So we
decided to quantify IgG deposits and MHC class II staining with the optical density
method instead of stereology. The images of the slices containing grafts were taken
with BZ-X700 and analyzed by Image J (ver. 1.37; NIH, USA) software. The
putamen in the section was manually deﬁned, and its optical density was adjusted
with those of the intact cortex and blank region of the slides (Fig. 7l).
Mixed lymphocyte reaction. We isolated PBMCs from monkey peripheral blood
using Ficoll-Paque Plus (GE Lifescience) or BD Vacutainer CPT (BD) following the
manufacturer’s protocols. PBMCs from the animals were suspended in RPMI-1640
(GIBCO) with 10% FCS and used as responder cells. For the stimulator cells,
PBMCs from the HT1 homozygous donor were treated with mitomycin C or
irradiation. Then, 1 × 105 responder PBMCs and 1 × 105 stimulator cells were
plated together in each well of 96-well U-bottom plates and incubated for 5 days.
The plates were pulsed with 1 mCi/well of 3H-thymidine (GE Healthcare) for the
ﬁnal 8 h, and the cellular uptake of 3H-thymidine was quantiﬁed by a liquid
scintillation counter, TRI-CARB 3100TR (Perkin Elmer). The stimulation index
was calculated with the formula, S.I.= the experimental value/non-stimulated
control value.
MRI and PET. MRI and PET studies were performed in accordance with and
approved by the Animal Care and Use Committee of RIKEN Kobe Institute
(MAH21-22). PET scans with 11C-PK11195 or (S)-11C-KTP-Me were performed
by an animal PET scanner (microPET Focus220; Siemens Medical Solutions)
to identify the activation of microglia after cell transplantation. High-resolution
T1-weighted and T2-weighted images were obtained using a 3T MRI scanner
(MAGNETOM Verio, Siemens AG). Before MRI and PET, animals were initially
sedated by an intramuscular injection of ketamine (10 mg/kg) with atropine
(0.1 mg/kg) and intubated. Animals were then deeply anesthetized and maintained
either by inhaled isoﬂurane (1.0%) during MRI or by continuous intravenous
infusion of propofol (10 mg/kg/h) during PET. At the beginning of a PET scan,
37MBq/kg of 11C-PK11195 or (S)-11C-KTP-Me was injected intravenously. The
scan with 3D list mode acquisition was performed for a duration of 90 min, and
the obtained data were sorted and reconstructed into 4D time-frame data. The
T1-weighted and T2-weighted MRI images were preprocessed for inhomogeneity
correction, motion, and brain segmentation using FREESURFER38 and NHP
version of HCP pipeline39. 11C-PK11195 and (S)-11C-KTP-Me were synthesized
using 11C-CH3I according to previous reports40, 41. PET images obtained at each
time point after transplantation (Pre, 1W, 1M, 2M, 3M) were co-registered with
MRI images obtained at the closest time point using boundary-based registration42
and corrected for partial volume effect using a region-based voxel-wise
correction43, 44 and segmentation data. The PET data of 11C-PK11195 was
estimated for the input function using a supervised algorithm (SUPERPK)45 and
analyzed for quantiﬁcation of BP using a simpliﬁed reference tissue model46, 47.
In the case of (S)-11C-KTP-Me, a linearized reference tissue parametric imaging
method, MRTM48, was used to quantify BP, and the cerebellum cortex was used as
the reference tissue. All images were structurally standardized into the macaque
MNI space49, and two slices were sectioned coronally and axially at y= 0 mm and
z= 3 mm in ACPC space for T1w, T2w, 11C-PK11195 BP and (S)-11C-KTP-Me
BP. BP values are shown with a color range from 0 to 1 for 11C-PK11195 BP
and from the 5th to 95th percentiles for (S)-11C-KTP-Me. A total of 222 scan
data (T1-weighted MRI= 56; T2-weighted MRI= 56; 11C-PK11195 PET = 56; and
(S)-11C-KTP-Me PET = 54) was fully automatically analyzed.
RT-PCR. The total RNA fraction was extracted using an RNeasy Mini kit (Qiagen)
and reverse-transcribed using Super Script III First-Strand Synthesis System
(Invitrogen). For PCR ampliﬁcation, reactions were performed using HotStarTaq
(Qiagen). Quantitative PCR reactions were carried out with Power Syber (Applied
Biosystems) according to the manufacturer’s instructions. The expression level of
each gene was normalized to that of GAPDH using the ΔCT method. Genomic
DNA was extracted using the DNeasy Blood and Tissue kit (Qiagen). Primers used
for the reactions are shown in Supplementary Table 3.
Statistics. Data are expressed as means± SD or means ± SEM, and the differences
were tested by commercially available Prism 6 software (GraphPad) and SPSS
software ver. 18.0 (IBM). P-values <0.05 were considered signiﬁcant.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
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